Germany And Netherlands Medical Marijuana Market Outlook 2031
The Germany and Netherlands medical marijuana market size was valued at USD 1.41 billion in 2022 and is projected to reach USD 4.24 billion by 2031 expand at a CAGR of 13 % during the forecast period, 2023–2031. The growth of the market is attributed to the increasing legalization for the use of marijuana in many countries for medical use and also its increasing usage in treatment of many chronic conditions.
Medical marijuana is used to treat diseases or ailments by using the marijuana plant or its compounds. It is essentially the same as recreational marijuana, except it's used for medical reasons. Cannabinoids are a group of chemicals found in marijuana plants that number in hundreds. Each has a distinct influence on the human body. The main chemicals utilized in medicine are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
When people smoke marijuana or eat foods containing THC, they get a "high". Chronic pain, cancer, depression, diabetes, arthritis, glaucoma, epilepsy, migraines, AIDS, and Alzheimer's disease are among the conditions for which medical marijuana is used.
On May 4, 2016, Germany's Cabinet adopted laws allowing seriously sick people who have obtained medical advice and "have no therapeutic alternative" to use cannabis. While, Cannabis is prohibited in the Netherlands, however it is decriminalized for personal use. Since 2003, an authorized prescription medicine called "Mediwiet" has been accessible in Dutch pharmacies. After the legalization of medical marijuana in Germany, the number of medicinal marijuana patients has risen from 1,000 to roughly 30,000-50,000.
Germany And Netherlands Medical Marijuana Market Trends, Drivers, Restraints, and Opportunities
- Growing number of countries making marijuana legal for medical purposes and also its increasing adoption are the factors which is expected to propel the market growth further during the forecast period.
- Increasing demand of medical marijuana therapeutic purposes is projected to drive the market growth during the forecast period.
- Advancements in technology, healthcare infrastructure, increasing patient awareness, and acceptance regarding medical marijuana treatment are the major factors which is anticipated to drive the market growth during the coming years.
- Increasing demand for marijuana extracts such as oils and tinctures, Germany held second-largest market share of cannabis oil imports is projected to boost the market growth in the forecast period.
- Sanctioning of medical marijuana for selected indications present as key challenge that can hamper the market growth during the forecast period.
- Complex regulatory framework for cannabis use is main factor that can impede the market growth in the coming years.
- Increased emphasis on R&D for novel product development is projected to offer lucrative opportunities for the market players.
Scope of The Germany And Netherlands Medical Marijuana Market Report
The report on the Germany and Netherlands medical marijuana market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Medical Marijuana Market - Germany and Netherlands Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Product (Flower and Oil), Application (Chronic pain, Mental Disorders, Cancer and Others)
|
|
Geographical Scope
|
Germany and Netherlands
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
ADREXpharma GmbH; Canopy Growth Corporation; Aphria Inc; Aurora Cannabis; Tilray; GW Pharmaceuticals; Organigram Holdings, Inc; The Cronos Group; Demecan GmbH; Cannamedical Pharma GmbH
|
Germany And Netherlands Medical Marijuana Market Segment Insights
Flower segment is expected to account for a key share of the market
Based on product, the Germany and Netherlands medical marijuana market is bifurcated into flower and oil. The flower segment is expected to account for a key share of the market during the forecast period owing to increasing preference for the usage of smoking flowers for therapeutic purposes. Moreover, the segment's rapid onset of action in relation to flower smoking and its uses in easing chronic pain, lowering cancer, and slowing the course of Alzheimer's illness is expected to drive growth.
On the other hand, the oil segment is anticipated to expand at a rapid pace during the forecast period due to its advantages over smoking flowers. Furthermore, doctors who prescribe it to their patients should keep track of how much CBD, THC, and other cannabinoids are ingested. Because quantifying this information from smoked marijuana is difficult, a growing number of doctors are prescribing oil and extracts to their patients in order to keep track of the amount used. As a result, the medical marijuana market in Germany and the Netherlands is likely to grow in the future years due to a growing preference for the use of oils.
Chronic pain segment is expected to constitute a key share of the market
Based on application, the Germany and Netherlands medical marijuana market is segmented into Chronic pain, Mental Disorders, Cancer and Others. The chronic pain segment is expected to constitute a key share of the market during the forecast period due to its increased acceptance in treatment of chronic conditions.
Furthermore, scientific evidence confirming its efficacy in the treatment of a variety of disorders, including chronic pain, is projected to drive market expansion throughout the forecast period. On the other hand, the mental disorders segment is anticipated to expand at a rapid pace during the forecast period owing to increased incidence of metal disorders. Furthermore, increasing healthcare expenditures for mental diseases are expected to drive the market growth.
Germany is anticipated to dominate the market
On the basis of geography, the Germany and Netherlands medical marijuana market is categorized as Germany and Netherlands. Germany is anticipated to dominate the market at an impressive CAGR during the forecast period. The regional market growth can be attributed to growing population, strong demand for medical services, and lenient government restrictions.
Furthermore, the BfArM granted licenses to Aurora Produktions GmbH, Aphria Deutschland GmbH, and Demecan GmbH to grow marijuana in the country in 2019. As a result, the approval of cultivation permits is expected to enhance market growth even more. On the other hand, Netherlands is expected to exhibit a rapid growth rate in the coming years due to improved supply of high-quality marijuana in the country and an increasing number of patients opting for the treatment.
Furthermore, a decrease in illegal marijuana sourcing as a result of positive government changes, combined with increased demand from licensed marijuana dispensaries, is expected to drive development throughout the forecast period.
Segments
The Germany and Netherlands medical marijuana market has been segmented on the basis of
Product
Application
- Chronic pain
- Mental Disorders
- Cancer
- Others
Geography
Key Players
- ADREXpharma GmbH
- Canopy Growth Corporation
- Aphria Inc
- Aurora Cannabis
- Tilray
- GW Pharmaceuticals
- Organigram Holdings, Inc
- The Cronos Group
- Demecan GmbH
- Cannamedical Pharma GmbH
Competitive Landscape
Key players competing in the Germany and Netherlands medical marijuana market are ADREXpharma GmbH; Canopy Growth Corporation; Aphria Inc; Aurora Cannabis; Tilray; GW Pharmaceuticals; Organigram Holdings, Inc; The Cronos Group; Demecan GmbH; Cannamedical Pharma GmbH.
Companies' strategic expansions in the form of mergers and acquisitions are predicted to increase competition and promote market growth. for example, in August 2019, Tilray entered into an arrangement with Cannamedical Pharma GmbH, a German company, to export USD 3.3 million worth of medical cannabis from Portugal to Germany through its German subsidiary, Tilray Portugal. Tilray's foothold in Germany will be strengthened as a result of this agreement.
Request For Customization
Enquiry Before Buying
Speak With Analyst
